Companies: 10,795·Total market cap: $144.5T
Rallybio Corporation

Rallybio Corporation

RLYBNASDAQHealthcare● Active
$16.23
+$0.32(+2.01%)
Market Cap$85988812
P/E Ratio
52W High$17.574
52W Low$2.4

Rallybio Corporation (RLYB) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

rlyb · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Rallybio Corporation (RLYB) measures how much investors pay for each dollar of the company's trailing earnings. RLYB's current PE ratio of N/A is calculated by dividing its stock price of $16.23 by its TTM earnings per share of -$1.37.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-5.52
Based on 1 analyst
EPS (TTM)
-$1.37
TTM · diluted EPS
PEG Ratio
-0.06
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Rallybio Corporation SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Rallybio Corporation
Rallybio CorporationYou
RLYB
$86MN/A-$1.37
Boundless Bio, Inc.
Boundless Bio, Inc.
BOLD
$32MN/A-$2.60
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$12MN/A-$6.64
iBio, Inc.
iBio, Inc.
IBIO
$28MN/A-$1.75
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc.
INTS
$7MN/A-$0.86
Iterum Therapeutics plc
Iterum Therapeutics plc
ITRM
$2MN/A-$1.26
Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc.
KLTO
$20MN/A-$0.32

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.59
2024-12-31
FY2024
$-10.61
2023-12-31
FY2023
$-14.75
2022-12-31
FY2022
$-16.76
2021-12-31
FY2021
$-11.71
2020-12-31
FY2020
$-9.51
2019-12-31
FY2019
$-6.34

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Rallybio Corporation (RLYB) measures how much investors pay for each dollar of the company's trailing earnings. RLYB's current PE ratio of N/A is calculated by dividing its stock price of $16.23 by its TTM earnings per share of -$1.37.

PE Ratio = Stock Price ÷ EPS (TTM)
= $16.23 ÷ -$1.37 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

RLYB pe ratio · 6 questions

RLYB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $16.23 and TTM EPS of -$1.37. Data sourced from Financial Modeling Prep via RLYB's SEC 10-K and 10-Q filings.

RLYB PE ratioWhat is RLYB PE ratioCurrent PE ratio of RLYBRLYB PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Rallybio Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09